Industry Updates

Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth

Published: 14/02/2026
Author: Fashion Value Chain

Akums Drugs & Pharmaceuticals Ltd. announced its financial results for the third quarter and nine months of FY26. The company reported revenue of ₹1,160 crore in Q3 FY26, an increase of 14.8% compared with ₹1,010 crore in the same quarter last year.

The company also recorded growth in adjusted EBITDA and adjusted profit after tax (PAT). Higher volumes, improved capacity utilisation and better performance across key business segments supported the quarterly results.

Key Business Performance in Q3 FY26

Akums’ Contract Development and Manufacturing Organisation (CDMO) business recorded revenue growth of more than 16%. Double-digit volume growth supported this performance.

Meanwhile, the international branded formulations segment more than doubled its revenue sequentially. The company attributed this increase to a recovery in demand across key markets.

Akums also continued to improve its API and trade generics businesses. Tighter overhead control and changes to its product portfolio helped reduce losses in these segments.

EBITDA and Profit Growth

Adjusted EBITDA increased by 21% year-on-year to ₹147 crore in Q3 FY26. The company reported ₹121 crore in the corresponding quarter last year.

Its adjusted EBITDA margin also improved to 12.7%, compared with 12% in Q3 FY25 and 9.3% in Q2 FY26.

Adjusted PAT rose by 29.5% to ₹86 crore from ₹66 crore a year earlier. The adjusted PAT margin increased to 7.2%, compared with 6.5% in Q3 FY25.

EU GMP Certifications and UK Regulatory Approval

Akums continued to expand its presence in regulated international markets. The company received European Union Good Manufacturing Practice (EU GMP) certification for two manufacturing facilities.

These approvals include the renewal of EU GMP certification for its Oral Solids plant. The company also received EU GMP certification for its Oral Liquids plant.

In addition, Akums received its first approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Rivaroxaban tablets.

Management Comments

Mr. Sandeep Jain, Managing Director, said, “The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams. We remain focused on disciplined growth while steadily strengthening our presence in regulated markets.”

Mr. Sanjeev Jain, Managing Director, added, “Our continued focus on operational excellence and disciplined growth is aligned with our long-term global vision, enabling us to expand responsibly across regulated markets and strengthen partnerships worldwide.”

Financial Highlights

The following table presents the company’s financial performance. All figures are in ₹ crore, except percentages and margins.

Particulars Q3 FY26 Q3 FY25 YoY change Q2 FY26 9M FY26 9M FY25 YoY change
Revenue 1,160 1,010 14.8% 1,018 3,201 3,063 4.5%
Adjusted EBITDA 147 121 21.0% 94 370 367 1.0%
Adjusted EBITDA Margin 12.7% 12.0% — 9.3% 11.6% 12.0% —
Adjusted PAT 86 66 29.5% 43 193 190 1.6%
Adjusted PAT Margin 7.2% 6.5% — 4.1% 5.9% 6.1% —

The results show stronger quarterly growth in revenue, EBITDA and PAT. However, nine-month adjusted EBITDA and adjusted PAT recorded more moderate year-on-year growth.

Related Posts

Symphony Orchestra of India’s (SOI) Spring 2024 Season Invites Concertgoers for Yet Another World-class Orchestral Experience

Amrita students win first prize at DecodeX 2025 hackathon

Asian School of Cyber Laws and GLC Mumbai Launch the Advanced Program on Cyber Law